S&P Futures
5,910.00 -10.00 (-0.17%) Dow Futures
43,439.00 -101.00 (-0.23%) Nasdaq Futures
20,600.00 -33.50 (-0.16%) Russell 2000 Futures
2,306.30 -11.40 (-0.49%) Crude Oil
68.61 -0.55 (-0.80%) Gold
2,632.70 +18.10 (+0.69%)
Invizyne Technologies Inc. Common Stock (IZTC)
| Previous Close | 11.12 |
| Open | 11.33 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 11.15 - 12.00 |
| 52 Week Range | 8.50 - 12.00 |
| Volume | |
| Avg. Volume | 45,465 |
| Market Cap | 21.281M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireInvizyne Technologies Announces Closing of Initial Public Offering
Monrovia, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the closing of its initial public offering of 1,875,000 shares of its common stock at a public offering price of $8.00 per share. The shares began trading on NASDAQ under the ticker symbol “IZTC” on November 13, 2024. The gross proceeds from the offering, bef
GlobeNewswireInvizyne’s Nasdaq IPO Marks New Era of Biomanufacturing
Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology Invizyne CEO Michael Heltzen comments on the company’s IPO Invizyne CEO Michael Heltzen comments on the company’s IPO Monrovia, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercia
